Emerging Growth Conference Announcement: The 85th Emerging Growth Conference is scheduled for August 20 & 21, 2025, focusing on companies with strong management and growth potential across various sectors.
Day 1 Schedule Highlights: Keynote speakers include CEOs from companies such as Immuron Limited, Nutriband, Inc., and Journey Medical Corporation, presenting their innovative products and strategies.
Day 2 Schedule Highlights: Presentations will feature executives from Eshallgo, Inc., Grove Collaborative Holdings, Inc., and U.S. Energy Corporation, among others, discussing their business developments.
Engagement and Participation: Attendees can register for the conference, submit questions to presenting companies, and access replays via the EmergingGrowth.com platform.
Wall Street analysts forecast DERM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DERM is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast DERM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DERM is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.360
Low
13.00
Averages
13.00
High
13.00
Current: 8.360
Low
13.00
Averages
13.00
High
13.00
Alliance Global
Buy
maintain
$10 -> $16
Al Analysis
2025-11-13
Reason
Alliance Global
Price Target
$10 -> $16
Al Analysis
2025-11-13
maintain
Buy
Reason
Alliance Global raised the firm's price target on Journey Medical to $16 from $10 and keeps a Buy rating on the shares post the Q3 report. The firm cites enthusiasm in the Emrosi launch for the target boost. It increased its peak revenue forecast to $250M from $200M for the drug.
H.C. Wainwright
Brandon Folkes
Buy
initiated
$13
2025-08-25
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$13
2025-08-25
initiated
Buy
Reason
H.C. Wainwright analyst Brandon Folkes initiated coverage of Journey Medical with a Buy rating and $13 price target. The firm believes the company's Emrosi has demonstrated clinical superiority to market leader Oracea in rosacea. This creates the potential for prescription demand and revenue pull through to exceed current consensus expectations, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DERM
Unlock Now
Lake Street
Buy
maintain
$9 -> $13
2025-08-13
Reason
Lake Street
Price Target
$9 -> $13
2025-08-13
maintain
Buy
Reason
Lake Street raised the firm's price target on Journey Medical to $13 from $9 and keeps a Buy rating on the shares after the company reported Q2 revenue higher than the firm's estimate and consensus. Though it is still early, signals from the ongoing launch of Emrosi "appear quite positive," the analyst tells investors in a post-earnings note.
B. Riley
Mayank Mamtani
Buy
maintain
$9 -> $12
2025-07-30
Reason
B. Riley
Mayank Mamtani
Price Target
$9 -> $12
2025-07-30
maintain
Buy
Reason
B. Riley analyst Mayank Mamtani raised the firm's price target on Journey Medical to $12 from $9 and keeps a Buy rating on the shares following a transfer of coverage. The firm expects increased visibility into Emrosi's early launch performance with the Q2 results in mid-August.
About DERM
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
